KIDS
Orthopediatrics·NASDAQ
--
--(--)
--
--(--)
KIDS fundamentals
Orthopediatrics (KIDS) released its earnings on Feb 26, 2026: revenue was 61.60M (YoY +16.97%), beat estimates; EPS was -0.26 (YoY +10.34%), beat estimates.
Revenue / YoY
61.60M
+16.97%
EPS / YoY
-0.26
+10.34%
Report date
Feb 26, 2026
KIDS Earnings Call Summary for Q4,2025
- Record Q4 Performance: 17% revenue growth ($61.6M) and $10M free cash flow, first positive quarter in company history.
- Profitability Expansion: 73% gross margin, $4.8M adjusted EBITDA (59% YoY increase), and 2026 guidance for $25M EBITDA and FCF breakeven.
- Innovative Product Launches: VerteGlide showing clinical success, 3P Hip beta launch exceeding expectations, and 10+ new products driving 2025 growth.
- Strategic Expansion: Entering cardiovascular and ENT markets with high-margin opportunities, and EU MDR approvals unlocking international growth.
- Digital Health Growth: 7D placements accelerating implant business, and Playbook beta launches targeting surgical efficiency.
EPS
Actual | -0.3 | -0.54 | -0.24 | -0.73 | -0.25 | -0.11 | -0.15 | -0.24 | -0.3 | -0.17 | -0.05 | -0.32 | -0.29 | -0.19 | -0.13 | -0.23 | -0.3 | -0.23 | -0.18 | -0.29 | -0.39 | -0.11 | -0.24 | -0.26 | |||||||||
Forecast | -0.2534 | -0.3815 | -0.3059 | -0.2735 | -0.2663 | -0.3214 | -0.2785 | -0.3075 | -0.3547 | -0.1885 | -0.1741 | -0.229 | -0.352 | -0.2049 | -0.2134 | -0.2685 | -0.4047 | -0.2629 | -0.2267 | -0.3007 | -0.4389 | -0.29 | -0.2584 | -0.2883 | |||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18.39% | -41.55% | +21.54% | -166.91% | +6.12% | +65.77% | +46.14% | +21.95% | +15.42% | +9.81% | +71.28% | -39.74% | +17.61% | +7.27% | +39.08% | +14.34% | +25.87% | +12.51% | +20.60% | +3.56% | +11.14% | +62.07% | +7.12% | +9.82% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | 16.36M | 13.59M | 22.20M | 18.92M | 21.46M | 26.70M | 25.08M | 24.81M | 23.42M | 32.93M | 34.95M | 30.99M | 31.59M | 39.56M | 39.97M | 37.61M | 44.69M | 52.80M | 54.57M | 52.67M | 52.41M | 61.08M | 61.25M | 61.60M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | 17.04M | 11.43M | 19.97M | 20.32M | 19.90M | 24.25M | 26.28M | 24.71M | 22.76M | 32.40M | 36.15M | 31.00M | 29.31M | 39.13M | 40.37M | 37.73M | 41.78M | 52.52M | 53.73M | 51.32M | 51.68M | 61.47M | 62.11M | 60.16M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4.02% | +18.92% | +11.20% | -6.85% | +7.86% | +10.06% | -4.59% | +0.42% | +2.88% | +1.63% | -3.33% | -0.02% | +7.77% | +1.09% | -0.99% | -0.31% | +6.95% | +0.53% | +1.57% | +2.63% | +1.41% | -0.63% | -1.39% | +2.40% |
Earnings Call
You can ask Aime
What were the key takeaways from Orthopediatrics’s earnings call?What does Orthopediatrics do and what are its main business segments?What is Orthopediatrics's gross profit margin?What is the revenue and EPS growth rate for Orthopediatrics year over year?What guidance did Orthopediatrics's management provide for the next earnings period?What is Orthopediatrics's latest dividend and current dividend yield?Did Orthopediatrics beat or miss consensus estimates last quarter?What were the key takeaways from Orthopediatrics's earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
